EarlyCDT®-Lung is a simple blood test which is ordered by a Doctor to aid in the risk assessment and early detection of lung cancer. The EarlyCDT-Lung test measures a panel of seven autoantibodies to detect the presence of lung cancer.
EarlyCDT-Lung has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
EarlyCDT-Lung offers a complementary approach to annual CT screening, seen as the gold standard in the USA for early lung cancer detection. As a simple blood test, EarlyCDT-Lung can be used when individuals are unwilling or unable to undergo lifelong, annual CT screening. It can also be used when an individual is at increased risk but does not meet the criteria for annual CT screening. In either case, a positive EarlyCDT-Lung result can be followed by suitable CTs at appropriate intervals in order to detect a lung cancer early, with the patient, physician and insurers better aware of the risk of cancer developing.
The EarlyCDT-Lung test can also be used in conjunction with diagnostic imaging techniques to further assess the risk of lung cancer being present where indeterminate lung nodules have been detected but have not been diagnosed as malignant.
This is not a genetic test for predisposition - a positive test may indicate the presence of the malignant disease. The test is sent to and performed in Oncimmune's CLIA-certified laboratory in the Kansas City area, USA. So far, over 145,000 EarlyCDT-Lung tests have been performed commercially through over 2,000 physicians. The test has aided in the detection of numerous early stage lung cancers. It is now also available in the UK and other regions.